In pharmaceutical manufacturing, much attention is often given to drug substance and drug product manufacturing sites. However, secondary packaging facilities – where products are packaged, labelled, and sometimes serialised before release – are equally subject to current Good Manufacturing Practice (cGMP) requirements and regulatory inspections.
The perception that “packaging-only” sites face lower compliance risk is a dangerous misconception. In reality, these facilities play a critical role in ensuring that medicines reach patients in the correct form, with accurate labelling and uncompromised quality. Any error in this stage can result in regulatory action, product recalls, or harm to patients.
Why Secondary Packaging Matters for Compliance
Secondary packaging encompasses activities such as:
- Applying printed labels and Patient Information Leaflets (PILs).
- Serialisation and application of unique identification codes.
- Assembly of multi-product kits.
- Repackaging into market-specific configurations.
Errors or lapses in these activities can directly impact patient safety, supply chain integrity, and product traceability. As such, regulators apply the same rigorous inspection principles to packaging sites as they do to manufacturing plants.
Common Compliance Risks in Secondary Packaging Sites
Audits of secondary packaging facilities frequently reveal:
- Labelling Errors
Incorrect product names, strengths, batch numbers, or expiry dates can lead to serious patient harm and product recalls. - Serialisation Failures
Missing or duplicate serial numbers compromise track-and-trace obligations and may breach anti-counterfeiting laws. - Data Integrity Issues
Inaccurate or incomplete documentation of packaging operations, particularly electronic batch records. - Environmental and Handling Non-Conformities
Poor temperature and humidity control during packaging of sensitive products. - Inadequate Line Clearance Procedures
Carry-over of materials from previous batches, leading to potential cross-contamination or mix-ups. - Weak Change Control
Insufficient assessment of the regulatory impact when making changes to labels, components, or packaging processes.
Regulatory Focus Areas
During inspections, authorities typically assess:
- Adherence to cGMP in packaging operations.
- Compliance with labelling regulations for target markets.
- Serialisation and traceability systems in line with FMD (Falsified Medicines Directive) or DSCSA (Drug Supply Chain Security Act) requirements.
- Personnel training and competency in GMP packaging procedures.
- Quality oversight to ensure deviations are recorded, investigated, and resolved.
How Q&V Helps Secondary Packaging Facilities Achieve Compliance
Q&V understands the unique operational pressures faced by secondary packaging sites. Our tailored compliance services include:
- GMP Compliance Audits – Assessing packaging processes, documentation, and controls to identify potential regulatory risks.
- Mock Inspections – Simulating regulator focus areas, including labelling, serialisation, and data integrity.
- Process Optimisation – Streamlining workflows to reduce error rates and improve batch record accuracy.
- Personnel Training – Ensuring packaging operators, quality assurance staff, and supervisors fully understand cGMP expectations.
- Serialisation Compliance Support – Validating systems and processes to meet EU and US track-and-trace requirements.
- Deviation and CAPA Management – Strengthening systems for root cause analysis and sustainable corrective actions.
With Q&V’s expertise, secondary packaging facilities can operate with the assurance that they are inspection-ready at all times, protecting both patient safety and market reputation.